The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
S. Al-Batran
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
R. Hofheinz
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
N. Homann
No relevant relationships to disclose
G. Illerhaus
No relevant relationships to disclose
U. M. Martens
No relevant relationships to disclose
J. Stoehlmacher-Williams
No relevant relationships to disclose
H. Schmalenberg
No relevant relationships to disclose
K. B. Luley
No relevant relationships to disclose
N. Prasnikar
No relevant relationships to disclose
M. Egger
No relevant relationships to disclose
S. Probst
No relevant relationships to disclose
J. T. Hartmann
No relevant relationships to disclose
M. H. Moehler
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
D. Arnold
No relevant relationships to disclose
W. Fischbach
No relevant relationships to disclose
C. Pauligk
Honoraria - Sanofi
S. P. Moenig
Honoraria - Sanofi
P. Piso
No relevant relationships to disclose
E. Jaeger
Research Funding - Sanofi